All manuscripts
Publications CAR T Cells G-Rex®6 Well Plate

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Published Journal Cancer Immunology Research

Share
No image preview

Overview

This study presents preclinical data for allogeneic CD20xCD22 CAR T cells. Cells were cultured in 10 cm G-Rex® or 6-well G-Rex® devices during the manufacturing process.

What this paper found

Allogeneic T cells engineered with a bicistronic CD20xCD22 dual CAR and TALEN-mediated TRAC and CD52 knockouts killed B-cell lymphoma targets that carried either antigen alone or both. Against Raji and JeKo-1 lines the dual CAR lysed cells dose-dependently and kept killing through repeated tumor challenges every three days for up to 11 days, while single CD22 CAR T cells lost control of CD20-positive, CD22-negative cells. In disseminated Daudi and subcutaneous Raji models, doses of 1, 3 and 10 million CAR-positive cells cleared tumor and extended survival, and the cells persisted in bone marrow beyond 100 days. Sixteen of 21 primary B-NHL samples were killed with IFN-gamma release, and a mantle cell lymphoma patient-derived xenograft responded at all three doses.

Note: Preclinical study in cell lines, primary patient samples and mouse models; the authors note that durability and long-term safety of allogeneic approaches still require long-term clinical study.

Here, we provide a robust preclinical proof of concept for, to our knowledge, the first allogeneic CD20xCD22 CAR as an alternative/additional therapy to CD19 CAR T cells — Beatriz Aranda-Orgilles, Isabelle Chion-Sotinel, Jordan Skinner, Steven Grudman, Ben Mumford, Chantel Dixon, Jorge Postigo Fernandez, Piril Erler, Phillipe Duchateau, Agnes Gouble, Roman Galetto, Laurent Poirot, Cancer Immunology Research

Study details

Authors
Beatriz Aranda-Orgilles, Isabelle Chion-Sotinel, Jordan Skinner, Steven Grudman, Ben Mumford, Chantel Dixon, Jorge Postigo Fernandez, Piril Erler, Phillipe Duchateau, Agnes Gouble, Roman Galetto, Laurent Poirot
Institution
Cellectis, Inc., New York, New York · Cellectis, SA, Paris, France
Journal
Cancer Immunology Research
Year
2023
PMID / PMC
PMID: 37257169 · PMC
G-Rex® model(s)
G-Rex®6 Well Plate
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

After lentiviral transduction and TALEN mRNA electroporation of activated PBMCs, the engineered T cells were moved into 10 cm G-Rex® or 6-well G-Rex® devices two days after transfection, using 35 mL of medium per vessel. IL2 was added at 20 ng/mL on day 11 and the medium was exchanged on day 13 with 5% Gibco CTS Immune Cell SR. Cells were expanded in these vessels until day 15 or day 18, then harvested and frozen at 50 to 100 million cells per mL.

Explore related

Full citation

Aranda-Orgilles B, Chion-Sotinel I, Skinner J, et al. Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies. Cancer Immunol Res. 2023;11(7):946-961.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →